Beijing's SL Pharma and Canada's PnuVax Form Vaccine, Antibody JV
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Beijing's SL Pharmaceutical announced it will invest CAD $20 million to form a joint venture in Ontario, Canada with Canadian partner PnuVax Incorporated.